- CorMedix (NASDAQ:CRMD) is up 16% premarket on above-average volume following its announcement of positive results from a Phase 3 clinical trial, LOCK-IT-100, evaluating its Neutrolin catheter lock solution in hemodialysis patients.
- Patients in the Neutrolin arm experienced 72% less risk of catheter-related bloodstream infections compared to the heparin control arm, well above the 55% assumed treatment effect. The separation from control was statistically significant (p=0.0034).
- The study was stopped early since efficacy was demonstrated after an interim analysis. No safety signals were observed.
- Management will host a conference call today at 4:30 pm ET to discuss the results.